Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
about
Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agentsCanadian clinical practice guidelines for invasive candidiasis in adults.Susceptibility of Candida spp. isolated from blood cultures as evaluated using the M27-A3 and new M27-S4 approved breakpointsMulticenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testMichael A. Pfaller, M.D.Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2.Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005.Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact.Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007.Trends in antifungal susceptibility testing using CLSI reference and commercial methods.Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Impact of new antifungal breakpoints on antifungal resistance in Candida speciesMolecular identification and in-vitro antifungal susceptibility testing of Candida species isolated from patients with onychomycosis.Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. anSelection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.Epidemiology of nosocomial candidaemia in a university hospital: a 12-year study.Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.
P2860
Q26863344-74E2D7B5-19E1-40B8-9A95-9FC604E984E7Q34237335-6635E75D-0A54-491C-BDDD-EFE6F0BE8267Q34977249-F466CF3C-7603-474F-A525-EC4F6CCB4F91Q35690728-D455F691-CF98-4A90-9653-05E3868CA35FQ35913918-5F68F77A-7ABC-46D8-A1EC-788471C86AFCQ36559020-DE914494-ADA6-40C0-85CA-D67D018F3D96Q36809333-50D2DC93-BB48-49AA-A2DE-7FBD8DF901E3Q37029222-B8212B07-CEDB-4438-95A8-45F5F3B53B5BQ37048679-1954B652-AD4B-4DB6-9A57-64A841567EADQ37374850-29EC6F77-5502-43C5-9435-6C8E9A930411Q37557695-BBE4CCEC-8997-4D0D-B451-F505A373C1C6Q37644219-A96EEE4D-380C-4BD7-B376-63F46BCCE592Q38285488-BD1D39C8-8108-491B-80EC-9F51962DB086Q38323404-B7A6F6D0-6724-4655-93EE-D1F59B708317Q38691907-B29CD934-1823-4E91-ADDB-369095D6C655Q39445046-0AF3C125-8324-4565-B304-5D7853313FFFQ39665961-70D48B0B-1C3E-4350-9BA4-164ED350D2C0Q40939764-4DE8182A-548F-4639-B55F-DFE8C274E07FQ41787736-22F2B12A-66D7-4B72-AAE1-E1F81FE97CBAQ41908678-0D0E6616-3989-4FA6-8886-B758A6F721EEQ42025836-7F4A8430-C239-4210-BC5D-3D8600BCBD85Q42078949-B2050BFE-5BF6-4A55-969F-DC0E833FA344Q42430237-E15401F6-2274-41FB-B059-3CAB6F9EF1EDQ42545839-639B0D39-082B-4362-863F-96CA39F0B973Q42727587-A01AB306-5838-496A-913D-22D64757FA7AQ43125888-61C1EC93-D99E-4FD7-A798-63FD2839949DQ43200250-7B0A88A2-FBED-4655-B8EB-1360427CFFE1Q46393306-3381C59D-E12E-4F8A-8A7E-231644891AF0Q46666432-70D17C16-D027-402D-9B5D-C6992F0CFA79Q46876288-C0172F08-C1C6-468E-BA4A-1AFF685384CDQ51175703-11677F4D-005B-461E-A386-A1B3E1C76B9B
P2860
Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Use of fluconazole as a surrog ...... d broth microdilution methods.
@en
Use of fluconazole as a surrog ...... d broth microdilution methods.
@nl
type
label
Use of fluconazole as a surrog ...... d broth microdilution methods.
@en
Use of fluconazole as a surrog ...... d broth microdilution methods.
@nl
prefLabel
Use of fluconazole as a surrog ...... d broth microdilution methods.
@en
Use of fluconazole as a surrog ...... d broth microdilution methods.
@nl
P2093
P2860
P356
P1476
Use of fluconazole as a surrog ...... d broth microdilution methods.
@en
P2093
D J Diekema
M A Pfaller
R J Hollis
S A Messer
S Tendolkar
P2860
P356
10.1128/JCM.01551-06
P407
P577
2006-11-01T00:00:00Z